Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Julie Epple

Registered Nurse, General Practice Festus, MO Nurse Practitioner

NPI 1043242183 CMS profile 10899837

1500 Calvary Church Rd, Festus, MO 63028

Open in the dashboard

General payments

$4,704

255 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Julie Epple of Festus, MO is reported in the CMS Open Payments database as having received $4,704 across 255 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Registered Nurse, General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,000 57
2024 General $1,338 71
2023 General $952 52
2022 General $686 36
2021 General $727 39

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Julie Epple
  • Registered Nurse, General Practice median
  • Middle half of Registered Nurse, General Practice
  • National median

In program year 2025, general payments to Julie Epple were reported at $1,000. Among 146 Registered Nurse, General Practice profiles paid that year, the median was $117 and the middle half received between $27 and $348.

Show as a table
Year Julie Epple Registered Nurse, General Practice median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $727 $92 $30–$313 $132
2022 $686 $85 $28–$243 $149
2023 $952 $121 $51–$290 $160
2024 $1,338 $127 $42–$316 $164
2025 $1,000 $117 $27–$348 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,870 95 payments
  2. AstraZeneca Pharmaceuticals LP $519 29 payments
  3. Lilly USA, LLC $396 21 payments
  4. Novo Nordisk Inc $353 21 payments
  5. Pfizer Inc. $172 11 payments
  6. Sumitomo Pharma America, Inc. $149 8 payments
  7. GlaxoSmithKline, LLC. $131 8 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $129 9 payments
  9. Exact Sciences Corporation $92 5 payments
  10. Eisai Inc. $85 2 payments
  11. Other $807 46 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,704 255 payments
Products named General payments · program years 2021–2025
  1. QULIPTA $850 38 payments
  2. UBRELVY $541 21 payments
  3. VRAYLAR Neuroscience $381 26 payments
  4. FARXIGA $280 15 payments
  5. Ozempic $266 16 payments
  6. RYBELSUS $263 16 payments
  7. MOUNJARO $219 10 payments
  8. TRULICITY $201 11 payments
  9. VRAYLAR Neuroscience $156 12 payments
  10. AIRSUPRA $152 8 payments
  11. Other $2,671 154 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 114 drugs

Part D claims

4,703

Median for Nurse Practitioner: 389

Drug cost

$218,918

Median for Nurse Practitioner: $21,885

Branded share of claims

18.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 23 $29,911
Ozempic Semaglutide Brand 14 $27,632
Jardiance Empagliflozin Brand 20 $21,324
Xarelto Rivaroxaban Brand 11 $15,222
Trulicity Dulaglutide Brand 11 $14,457
Nurtec Odt Rimegepant Sulfate Brand 13 $13,062
Myrbetriq Mirabegron Brand 18 $10,890
Linzess Linaclotide Brand 13 $10,130
Symbicort Budesonide/Formoterol Fumarate Brand 27 $8,152
Repatha Sureclick Evolocumab Brand 13 $6,941

The 10 drugs with the highest cost, of 114 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$35,103

Of which drugs: $3,293

Medicare patients

178

Average age 71

Services billed

515

119 women, 59 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Diabetes 33%
Depression 33%
Chronic kidney disease 31%
Ischemic heart disease 29%
Cancer 21%
Heart failure 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 36 36 $2,936

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
  • AbbVie, Inc. $339
$339 — —
VRAYLAR
  • AbbVie, Inc. $138
$138 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $121
$121 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $99
$99 — —
MOUNJARO
  • Lilly USA, LLC $91
$91 23 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

255 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Registered Nurse, General Practice in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record